ON
← Back to feed
They restricted the sale of a number of medicines and medical supplies due to several irregularities
AR🏛️ PoliticsCenter

They restricted the sale of a number of medicines and medical supplies due to several irregularities

Argentina's national health regulatory agency, ANMAT, has prohibited the pharmaceutical company KINFARMA S.A. from selling medications and medical products outside the province of Buenos Aires. This restriction was issued via Resolution 7338/2026 after a complaint alleged irregularities in the firm's operations. Although KINFARMA holds valid provincial authorization, it lacked the required national registration for interstate commerce. Provincial inspections revealed documentation proving the company had been delivering goods to healthcare providers across different jurisdictions without proper federal clearance. Consequently, ANMAT initiated a sanitary proceeding against the company and its technical director for violating specific health laws. The ban remains in effect until the firm obtains the necessary national permits.

Go to the primary sources (4)

The official sources this coverage is built on. Read them directly to bypass framing.

2 reports

La Nación logoLa NaciónIndependent🔒Center
Anmat banned the sale of a number of medical supplies due to irregularities and counterfeiting

The National Administration of Medicines, Foods and Medical Technology (Anmat) has banned the sale of several medical products due to counterfeiting and labeling irregularities. Through four official decrees published in the Official Gazette, Anmat restricted the commercialization of items such as 'Fresh & Clean' ethanol, 'DYSPORT 500,' and 'Canna Oil.' These products were either unregistered or falsely labeled, posing potential health risks. The agency emphasized that companies must obtain national authorizations before operating. Additionally, certain animal nerve tissue extracts were prohibited due to possible risks of transmitting neurodegenerative diseases.

Bias read (Center): The article presents factual information without overtly favoring any side, citing official actions and regulatory measures taken by Anmat based on reported violations.

Infobae logoInfobaeIndependentCenter
They restricted the sale of a number of medicines and medical supplies due to several irregularities

Argentina's national health regulatory agency, ANMAT, has prohibited the pharmaceutical company KINFARMA S.A. from selling medications and medical products outside the province of Buenos Aires. This restriction was issued via Resolution 7338/2026 after a complaint alleged irregularities in the firm's operations. Although KINFARMA holds valid provincial authorization, it lacked the required national registration for interstate commerce. Provincial inspections revealed documentation proving the company had been delivering goods to healthcare providers across different jurisdictions without proper federal clearance. Consequently, ANMAT initiated a sanitary proceeding against the company and its technical director for violating specific health laws. The ban remains in effect until the firm obtains the necessary national permits.

Bias read (Center): The article relies exclusively on official regulatory documents and administrative actions, presenting the enforcement of existing health laws without employing loaded language or partisan framing.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories